MedTrace Logo

Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer

NCT02785146 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2016-06-08

No results posted yet for this study

Summary

A randomized, paralleled control clinical study investigating Huaier Granule for prevention of recurrence and metastasis of colorectal cancer after radical surgery, to evaluate the efficacy and safety.

Conditions

Interventions

DRUG

Huaier Granule

Huaier Granule is continuously taken three times per day, 20g per time.

DRUG

Oxaliplatin

85 mg/m², ivdrip, D1

DRUG

Calcium folinate

Calcium folinate 400 mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1

DRUG

5-fluorouracil

400 mg/m², iv, D1; and 2400mg/m², civ, 48h

Sponsors & Collaborators

  • Qidong Gaitianli Medicines Co., Ltd

    collaborator INDUSTRY

  • Sixth Affiliated Hospital, Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Xiaojian Wu, Ph.D. · Sixth Affiliated Hospital, Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2018-01-31
Completion
2018-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02785146 on ClinicalTrials.gov